Pyrazinamide derivatives and processes for their preparation

ABSTRACT

A NEW METHOD IS DISCLOSED FOR THE PREPARATION OF PYRAZINAMIDE DERIVATIVES. THE PROCESS INVOLVES REACTION OF AN AMINE DERIVATIVE WITH A VERY REACTIVE PYRAZINOYLOXYACRYLAMIDE PREPARED BY REACTION BETWEEN A PYRAZINOIC ACID AND AN ISOXAZOLIUM SALT. THE RECTIVITY OF THE PYRAZINOYLOXYACRYLAMIDE PERMITS THE PREPARATION OF COMPOUNDS PREVIOUSLY UNAVAILABLE AND HENCE MANY OF THE PRODUCTS ARE NEW COMPOUNDS. THE COMPOUNDS PREPARED BY THIS PROCESS HAVE UTILITY AS DIURETICS.

United States Patent 3,577,418 PYRAZINAMIDE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION Edward I. Cragoe, In, Lansdale, and Kenneth L. Shepard,

gnJlbler, Pa., assignors to Merck & Co., Inc., Rahway,

N0 Drawing. Continuation-impart of application Ser. No.

718,976, Mar. 21, 1968, which is a continuation-in-part of application Ser. No. 666,004, Sept. 7, 1967. This appplicafion Feb. 12, 1969, Ser. No. 798,809

Int. Cl. C07d 51/76 US. Cl. 260-250 49 Claims ABSTRACT OF THE DISCLOSURE A new method is disclosed for the preparation of pyrazinarnide derivatives. The process involves reaction of an amine derivative with a very reactive pyrazinoyloxyacrylamide prepared by reaction between a pyrazinoic acid and an isoxazolium salt. The reactivity of the pyrazinoyloxyacrylamide permits the preparation of compounds previously unavailable and hence many of the products are new compounds. The compounds prepared by this process have utility as diuretics.

This application is a continuation-in-part of our copending US. application, Ser. No. 718,976 filed Mar. 21, 1968, which in turn is a continuation-in-part of our copending application, Ser. No. 666,004, filed Sept. 7, 1967, both applications having been abandoned.

This invention relates to a new process for the preparation of amide derivatives (III) of pyrazinoic acid, to certain new pyrazinamides (III) and to the intermediate pyrazinoyloxyacrylamides (I). In particular it relates to the process for the preparation of 3-amino-5,6-disubstituted-pyrazinamides, and certain N-derivatives which comprises the reaction of a 3-amino-5,6-disubstitutedpyrazinoyloxyacrylamide with an amine derivative (II). The invention also relates particularly to certain new amide derivatives of 3-amino-5,6-disubstituted-pyrazinoic acids including pyrazinamides, pyrazinoic acid hydrazides, pyrazinolyarnidines, 1-pyrazinoyl-3-hydroxy(and alkoxy) guanidines, and pyrazinoylbiguanides. It also relates to the novel intermediate (3-amino-5,G-disubstituted-pyrazinoyloxy)acrylamides. The process is represented by the following Method A:

wherein in each of the foreging structures R represents (a) Hydrogen,

(b) Lower alkyl of from 1 to about carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl and the like,

(c) Lower alkenyl of from 3 to about 5 carbon atoms, e.g., allyl, 2-butenyl, and the like,

(d) Lower alkynyl of from 3 to about 5 carbon atoms, e.g., propargyl and the like,

ice

(e) Lower cycloalkyl of from 3 to about 6 carbon atlfms, e.g., cyclopropyl, cyclopentyl, cyclohexyl and the (f) Lower cycloalkyl-lower alkyl wherein the cycloalkyl moiety contains from 3 to about 6 carbon atoms and the lower alkyl moiety contains from 1 to about 3 carbon atoms e.g., cyclopropylmethyl, 1- or 2-cyclopropylethyl, 1-, 2- or 3-cyclopropylpropyl, cyclopentylmethyl, 1- or 2-cyclopentylethyl, 1-, 2-, or 3-cyclopentylpropyl, cyclohexylmethyl, 1- or 2-cyclohexylethyl, 1-, 2- or 3-cyclohexylpropyl and the like,

(g) Di(lower alkyl)aminomethyl-lower alkyl, wherein each of the lower alkyl groups has from 1 to about 3 carbon atoms, and can be similar or dissimilar groups selected from methyl, ethyl, propyl and isopropyl e.g., dirnethyl-, diethyl-, diisopropyl, dipropyl-, N-methyl-N- ethyl, N-methyl-N-propyl, N-ethyLN-propyl, and the like,

(h) Hydroxy-lower alkyl, containing from 1 to about 5 hydroxyl groups and from 2 to about 6 carbon atoms e.g., 2-hydroxyet-hyl, 2, and 3-hydroxypropyl, pentahydroxyhexyl, and the like,

(i) w,w,w-Trifluoro-lower alkyl of from 1 to about 3 carbon atoms such as trifluoro-methyl, trifluoroethyl, trifluoropropyl and the like,

(j) Mononuclear aryl-lower alkyl, especially phenyllower alkyl, wherein the lower alkyl moiety contains from 1 to about 3 carbon atoms either straight or branched chain, and the phenyl group is either unsubstituted or substituted, with such as halo, e.g., benzyl, phenethyl, 1, 2, or 3-phenylpr0pyl, fiuorobenzyl, fluorophenethyl, chlorobenzyl, chlorophenethyl, and the like, 1

(k) Heterocyclic-lower alkyl, wherein the heterocyclic moiety is a 5 or 6 membered ring, containing oxygen or nitrogen or both, such as furyl, pyridyl and the like, and the lower alkyl moiety has from 1 to 3 carbon atoms either straight or branched chain, e.g., methyl, ethyl, propyl and the like,

(1) Mononuclear aryl, especially phenyl, either unsubstituted or substituted, such as with halogen, e.g., chloro and fluoro, or lower alkyl of from 1 to 3 carbons such as methyl, ethyl, propyl and the like,

(m) Lower alkoxy of from 1 to about 3 carbon atoms such as methoXy, ethoxy, propoxy, isopropoxy and substituted lower alkoxy such as aryl-lower alkoxy, for example benzyloxy and the like,

(11) Amino.

R represents (a) hydrogen, (b) lower alkyl of from 1 to about 5 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl and the like.

R and R when each represents lower alkyl, may be linked together, either directly or through a hetero atom to form a cyclic structure with the nitrogen atom to which they are attached, such as l-pyrrolidinyl, piperidino, hexahydro-l-azepinyl, 4-methyl-1-piperazinyl, and the like.

*R represents (a) lower alkyl of from 1 to about 3 carbon atoms, such as methyl, ethyl, propyl, or isopropyl, (b) mononuclear aryl, especially phenyl, either unsubstituted or substituted, with for example lower alkyl such as methyl, ethyl and the like, or with a sulfonate anion 0 form R represents hydrogen, or a hydrocarbon radical which when linked to R forms with the carbon atoms to which R and R are joined an ortho-phenylene group. I

R represents lower alkyl of from 1 to about 5 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl, and the like.

halo represents (a) chloro, (b) bromo, (c) or iodo.

R represents (a) Lower alkyl of from 1 to about 5 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl, and the like, either unsubstituted or substituted with such as "(1) Mono(lower alkoxy)methyl, wherein the lower alkoxy group has from 1 to about 3 carbon atoms, e.g., methoxy, ethoxy, propoxy, isopropoxy and the like,

(2) Di(lower alkoxy)methyl,

(3) Cyano,

(4) Lower alkoxycarbonyl, such as methoxyethoXy-, propoxycarbonyl, and the like,

(,5) 'Guanidinocarbonyl,

(6) Guanidinoaminocarbonyl,

(7) Heterocyclic-lower alkyl-aminocarbonyl, wherein the heterocycle is linked through a nuclear nitrogen atom and contains up to 1 other nuclear hetero atom selected from oxygen and nitrogen, which when nitrogen can be substituted with lower alkyl e.g., morpholino, pyrrolidinyl piperidino, and 4-methylpiperazino,

(8) Mononuclear aryl, especially phenyl,

(9) Di(lower alkyl)aminomethyl, wherein the lower alkyl groups can be similar or dissimilar, and each has from 1 to about 3 carbons, e.g., methyl, ethyl, propyl and the like,

(10) Heterocyclic aminomethyl, wherein the heterocyclic group is of 5 or 8 atoms containing 1 or 2 nitrogen and/ or oxygen atoms such as 2(2-imidazolinyl), and the like,

(11) Heterocyclic of 5 to about 8 atoms containing 1 or 2 oxygen and/or nitrogen atoms, and either unsubstituted or substituted advantageously with lower alkyl having preferably 1 to 3 carbons e.g., l-pyrrolidinyl, piperidino, heXahydro-l-azepinyl, morpholino, 4-methyll-piperazinyl, pyridyl, furyl, tetrahydropyranyl, and the like,

(b) Mononuclear aryl, especially phenyl, either unsubstituted or substituted advantageously with halo, e.g., chloro, or bromo, lower alkyl of from 1 to about 3 carbons, e.g., methyl, ethyl, propyl and the like, or lower alkoxy of from 1 to about 3 carbon atoms e.g., methoxy, ethoxy, propoxy, and the like,

Lower alkenyl of about 3 to carbon atoms, e.g., allyl, 2-butenyl and the like,

(d) Lower alkynyl of about 3 to 5 carbon atoms, e.g., propargyl, and the like,

(f) Amino, either unsubstituted, or di-substituted with such as lower alkyl of from 1 to about 3 carbon atoms selected from among e.g., methyl, ethyl, propyl and the like, mononuclear aryl-lower alkyl, especially phenyllower alkyl, such as benzyl, phenethyl, l, 2, or 3-phenylpropyl and the like, or monosubstituted with groups such as a heterocyclic radical such as 2-, 3-, or 4-pyridyl, 2- pyrimidinyl, 2-quinolinyl, and the like,

(g) Heterocyclic radical of from 5 to about 8 nuclear members which can contain one nitrogen atom and up to 2 other heteroatoms selected from sulfur, oxygen and nitrogen, e.g., l-pyrrolidinyl, l-piperidino, l-hexahydrol-azepinyl, morpholino, 4-(3,5-diamino-1,2,4-triazolyl), triazolyl, pyridyl, pyrimidinyl, oXazolinyl, triazolinyl and the like either unsubstituted or substituted with lower alkyl of 1 to about 3 carbon atoms, or phenyl,

H wherein R represents (1) Lower alkyl of from 1 to about 5 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl, and the like,

(2) Mononuclear aryl, especially phenyl, either unsubstituted or substituted with such as halo, e.g., chloro or bromo, lower alkyl of from 1 to about 3 carbon atoms, e.g., methyl, ethyl or propyl, or lower alkoxy of from 1 to about 3 carbon atoms, e.g., methoxy, ethoxy, or propoxy,

(i) -C-NR"R wherein R represents 1) hydrogen, (2) lower alkyl of from 1 to about 5 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl and the like, (3) mononuclear aryl, such as phenyl,

=R represents (1) hydrogen, (2) lower alkyl of from 1 to about 5 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl, and the like, either unsubstituted or substituted with such as (a) hydroxy, (b) aryl, either monoor dinuclear aryl, especially phenyl and naphthyl, either unsubstituted or substituted with such as halo, e.g., chloro, bromo, or fluoro or with lower alkyl, e.g., methyl, ethyl, propyl, isopropyl, and the like, or lower alkoxy of from 1 to 3 carbons, e.g., methoxy, ethoxy or propoxy, (c) heterocyclic radical of 5 to about 7 atoms containing 1 or more oxygen and/or nitrogen :atoms, e.g., 2-, 3-, or 4-pyridyl, morpholino, l-pyrrolidyl and the like, ((1) lower alkoxy of from 1 to about 3 carbon atoms, e.g., methoxy-ethoxy, propoxy, and the like.

(3) Lower alkenyl of from 3 to about 5 carbon atoms, e.g., allyl, 2-, or 3-butenyl, 2-, 3- or 4-pentenyl and the like,

(4) Lower alkylideneamino such as isopropylideneamino, and the like,

(5) Mononuclear aryl-lower alkylideneamino, especially phenylalkylideneamino, e.g., benzylidene-amino, and the like,

(6) Hydroxy,

(7) Alkoxy, preferably lower alkoxy of from 1 to about 3 carbon atoms, e.g., methoxy, ethoxy, or propoxy,

(8) 'Mononuclear aryl-lower alkoxy, such as benzyloxy, phenethyloxy and the like,

(9) Mononuclear aryl, especially phenyl, either unsubstituted or substituted such as with halo, e.g., chloro, bromo or fiuoro, lower alkyl, e.g., methyl, ethyl, or propyl, i lower alkoxy, e.g., methoxy, ethoxy, propoxy, or the (10) Cyano, and

(11) Nitro,

R represents (1) hydrogen, (2) lower alkyl of from 1 to about 5 carbon atoms e.g., methyl, ethyl, propyl, islopropyl, butyl, pentyl, isopentyl, neopentyl, and the R and R when lower alkyl can be linked together, either directly or through a hetero atom to form a 58 atom cyclic structure with the nitrogen atom to which they are attached e.g., l-pyrrolidinyl, piperidino, hexahydro-l-azepinyl, morpholino, and the like, and

R and R when lower alkyl, may be linked together to form a 5-7 atom cyclic structure with the nitrogen atoms to which they are attached, e.g., a 2-(l,3-diaza-2- cycloalkene) such as, 2-(2-imidazolinyl), or 2-(l,4,5,6- te-trahydropyrimidyl) 2- 4,5 ,6,7-tetrahydro- 1H- 1 ,3-diazepinyl) and the like,

NHG--NR R N R18 wherein R represents (1) hydrogen, (2) lower alkyl of from 1 to about 5 carbon atoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl, and the like,

R represents (1) hydrogen, (2) lower alkyl of from 1 to about 5 carbon atoms e.g., methyl, ethyl, propyl,

NE NH u S O zN wherein R represents (1) hydrogen, (2) lower alkyl of 1 to about 3 carbons, (3) mononuclear aryl, especially phenyl, (4) phenyl-lower alkyl, wherein the lower alkyl group has from 1 to about 3 carbon atoms, and

R represents (1) hydrogen, (2) lower alkyl of from 1 to about 3 carbon atoms,

R represents hydrogen or lower alkyl;

R and R when lower alkyl, can be linked together, either directly to form a saturated heterocycle of 3 to 6 members with the nitrogen atom to which they are attached, or through a hetero atom selected from oxygen and nitrogen to form a saturated 6 membered heterocycle, such as morpholine, 4-methylpiperazine, and the like.

Another embodiment of this invention is the 3-amino- S-NR R -6-halopyrazinoyloxyacrylamides of structural R R' O wherein R R R R R and halo each have the meaning heretofore assigned. These novel compounds as well as the novel process of this invention are useful in preparing amide derivatives of pyrazinoic acids, which derivatives can be classified as pyrazinamides, pyrazinoic acid hydrazides, pyrazinoylamidines, pyrazinoylguanidines, pyrazinamidoguanidines, pyrazinoylbiguanides, and pyra- Zinoylsulfamides, which products in turn have utility as diuretic or saluretic agents in the management of conditions that manifest symptoms of excessive water and/or salt retention.

Prior to the present invention many of the pyrazinamides (III) described herein were prepared by reaction of the appropriate amino compound and an alkyl pyrazinoate. However, it was found that often, these esters failed to react or they reacted very slowly. Application of more severe reaction conditions usually only increased the amount of side reactions. Hence, a more reactive derivative of the pyrazinoic acids Was required. Surprisingly it was found that the pyrazinoyloxyacrylamides of this invention are extremely reactive derivatives. They are readily prepared by Method B and are readily converted to the amide structures as shown in process A of this invention.

Method B 4 N tertiar amine /o halo coon N H fe R x IV N NH3 32 halo CO---C=CCONHR N H l I O R R The Rs in the above structures have the meanings assigned above. Approximately equivalent amounts of a pyrazinoic acid, IV, an isoxazolium salt, V, and a tertiary amine, are dissolved in a solvent and stirred. Generally the pyrazinoic acid and tertiary amine such as a tri(lower alky1)amine e.g., trimethylarnine, triethylamine, tripropylamine or the like are dissolved in a solvent such as dimethylformamide, dimethyl sulfoxide, dimethyl sufone, acetonitrile, tetrahydrofuran or the like, preferably dimethylformamide or acetonitrile, and stirred for a period of from a few minutes to several hours. The isoxazolium salt then is added and the mixture stirred for from about one to about four hours, usually about two hours at ambient temperature, although gentle heating up to about 50 C. can be employed. The product, I, usually is sufficiently stable to be isolated and purified; it is often isolated simply by diluting the reaction mixture with water which precipitates the pyrazinoyloxyacrylamide. Alternatively, the product (I) may be obtained by evaporation of the reaction mixture. These products then can be recrystallized, usually from a polar organic solvent, such as acetonitrile, isopropyl alcohol or the like.

It is possible, and sometimes preferable, not to isolate these intermediate pyrazinoyloxyacrylamides, but rather to proceed directly with the process of this invention wherein this intermediate is used in situ and converted to the desired substituted pyrazinamide (II-I). Such reaction is represented by a combination of Method B followed by Method A. In this instance about one hour after the reagents IV and V and the tertiary amine have been mixed, about one to ten equivalents of the amine (II) is added and the reaction mixture is stirred at a temperature from about ambient to about C. for from two to about 24 hours. The resulting amide then is isolated by dilution of the reaction mixture with water, or in some cases with an alcohol such as ethanol or isopropyl alcohol, which precipitates the desired substituted amide.

Where it is found desirable to first isolate the intermediate pyrazinoyloxyacrylamides, (I), the reaction is conducted essentially as described above except that the preformed (I) and the amino compound, (II), are mixed in a molar ratio of from 1:1 to about 1:10 in a solvent such as dimethylformamide, dioxane, dichloromethane, tetrahydrofuran, acetonitrile or t-butyl alcohol, or the like, preferably tetrahydrofuran or acetonitrile and the mixture is stirred for from 2 to about 24 hours at temperatures ranging from ambient to reflux temperature. The time and temperature required depends on the nature of the reactants.

In some instances it has been found necessary to first form the anion of the amine reactant, II, by adding to it an equivalent of a strong base such as sodium hydride.

The intermediate pyrazinoic acids are generally prepared by the hydrolysis of the corresponding methyl esters (VI) as shown below. The hydrolysis is usually carried out using a solution of aqueous base, such as, sodium hydroxide or potassium hydroxide and a solvent such as, isopropyl alcohol, ethanol and the like, and refluxing the mixture for one to 10 hours. The pyrazinoic acid then is isolated by cooling and acidifying the mixture with an acid, such as hydrochloric acid, sufuric acid and the like.

N N \N/ NH. N-/ NH2 11/ 1 R/ 1 halo 000cm halo 00011 vr iv The following examples described the preparations of the various pyrazinoic acid starting materials, the intermediate pyrazinoyloxyacrylamides and the process of this invention by the preparation of several types of substituted amide derivatives, classified as pyrazinamides, pyrazinoic acid hydrazides, pyrazinoylamidines, pyrazinoylguanidines, pyrazinamidoguanidines, pyrazinoylbiguanides and pyrazinoylsulfamides.

PREPARATION OF PYRAZINOIC ACIDS Example 1 3,5-diamino-6-chloropyrazinoic acid.--A mixture of finely ground methyl 3,S-diamino-6-chloropyrazinoate (101.31 g., 0.50 mole), isopropyl alcohol (1875 ml.) and aqueous sodium hydroxide solution (625 ml.) is heated under reflux, with 'vigorous stirring, for one hour. Water (7500 ml.) is added to the cooled reaction mixture and the resulting clear solution is made acid to Congo red paper by the addition of concentrated hydrochloric acid. The light yellow solid 'which separates is collected and dried, yield 92.8 g. (98.4%), M.P. 230-1 C. (dec.). Recrystallization from dimethyl sulfoxide-Water gives 3,5-diamino-6-chloropyrazinoic acid, M.P. 272 C. dec.

Analysis.Calcd for C H CLN O (percent): C, 31.84; H, 2.67; N, 29.71. Found (percent): C, 32.10; -H, 2.65; N, 29.57.

Example 2 3-amino-5- (2-propynylamino) -6-chloropyrazinoic acid Step A: Preparation of methyl 3-amino-5-(2'propynylamino)-6-chloropyrazinoate.2-propynylamine (3.60 g., 0.065 mole) is added to a suspension of methyl 3-amino- 5,-6-dichloropyrazinoate (7.20 g., 0.0325 mole) in dimethyl sulfoxide (80 ml.). The resulting clear solution is stirred for one hour and diluted with water (240 ml.). The solid which separates is collected and dried, 7.75 g. (99%), M.P. 160-2 C. Recrystallization from actonitrile gives off-white prisms, M.P. 168-9 C. of methyl 3-amino- 5-(2-pro-pynylarnino)-6-chloropyrazinoate.

Analysis.-Calcd for C H ClN O (percent): C, 44.92; H, 3.77; N, 23.28. Found (percent): C, 44.82; H, 3.73; N, 23.09.

Step B: Preparation of 3-amino-5-(2-propynylamino)- 6-chloropyrazinoic acid.-Utilizing the procedure substantially as described in Example 1, but substituting for the methyl 3,5- diamino-6-chloropyrazinoate employed therein, an equimolar amount of methyl 3-amino-5-(2- propynylamino)-6-chlor0pyrazinoate there is produced 3- amino-S-(2-propynylamino)-6-chloropyrazinoie acid.

Employing substantially the same procedure as that described in Example 1, but substituting for the methyl 3,S-diamino-6-chloropyrazinoate used therein, equimolecular quantities of the methyl 3-amino-5-NR R -6-halopyrazinoates described in Table I there are produced the 3-amino-5-NR R -6-halopyrazinoic acids also described in Table I.

TABLE I N -NHz N NH2 R 12 I halo COO CH3 halo C O OH R R halo Example:

3 H H I H H Br 5 C2H H Cl 6 CHz=CHCHz- H G1 7 H Cl 8 'CH2- H 01 9 (CHa)2N(CH2)z- H Cl 10 HOCHzCHr- H Cl 11 HOCH2(CHOH)4CHz- H Cl derived from Dzglueamine). l2 CFaCHz- H Cl 13 Q-om- H or F l 14 om 01 O H C1 CH3- Cl CH3- Cl (3113- C1 (CHz)4 Cl PREPARATION OF PYRAZINOYLOXYACRYL- AMIDES Example 22 N (t butyl) 3 methyl 3 (3,5 diamino 6- chloropyrazinoyloxy) acrylamide.A mixture of 3,5 diamino-6-chloropyrazinoic acid (1.90 g., 0.01 mole) and triethylamine (1.0 g., 0.01 mole) in dimethylformarnide (20 ml.) is stirred for 10 minutes. N-(t-butyD-S-methylisoxazolium perchlorate (2.40 g., 0.01 mole) is added and the resulting solution stirred for 2 hours. Water ml.) is added and the solid which separates is collected and dried. The yield is 2.85 g. (87%); M.P. 1716 C. Recrystallization from acetonitrile gives light yellow crystals, M.P. 187-9 C., of N-(t-butyl)-3-methyl-3-(3,5- diamino-6-chloropyrazinoyloxy) acrylamide.

Analysis.-Calcd for C H ClN O (percent): C, 47.63; H, 5.53; N, 21.37. Found (percent): C, 47.87; H, 5.55; N, 21.42.

Employing the procedure substantially as described in Example 22, but substituting for the 3,5-diamino-6-chloropyrazinoic acid and the N- (t-butyl)-5-methyl-isoxazolium perchlorate utilized therein, equivalent amounts of 3- amino-5-NR R -6-halopyrazinoic acid and N-R -5-R -4- R -isoxazolium salt respectively which are described in Table II, there are produced the N-R -2R -3-R -3-(3- amino 5 NR R 6 halo pyrazinoyloxy)acrylamides, also described in Table II.

TABLE II R3 R1 R4 R1 N N \N/ NH2 \N NH; o 2Hs)aN 5 halo \N COOH H hal \N o o CONH R I 9 o R3 R4 R5 X R R R R4 R x halo Example I 23 H H OQSQ H CH OHzr 24 H H Q- H (CH3);C (110, Br

N02 25 0H1=CH0H2- H -CH=CHCH=OH(2) 0H.- WNQ-SO? c1 26 HCEC-CHZ- H CH H (OH3)3C-- 010. c1

27 H Same H Same Same as above 01 I 28 -oH2 H OQSQ H cH3oH2 c1 29 oHmNwHm- H CH3- H (CH3)3O-- 010., c1 30 HOCHzCHz- H Same H Same .i Same as above Cl 31 HooHz oHoH .,oHz H CH=CHCH=CH(2) CH onv -soa 01 32 CF3CH2 H Q- H (CH C- 010. 01

33 Q-ww- H om- H Same-- Same as above 01 l l 34 -0H2 H o3s H CH3CH- c1 0 9 as 4315? H CH3- H (CHmC- 010. or

36 H Same H Same Same as above Cl 37 o1- H -CH=CHCH=CH(2) om- OzNQ-S 02 01 38 CH3O CH H (CH3)3C-- 010. 01

39 NHz- Same.-. CH;;- H Same Same as above Cl 40 -(CH2)4- Same H do do C1 40 0.... CH3 CH3- ....d0 H d0 0 4" C1 40(,,-)-... CzI-Is- H 0 H do Same as above C1 1 The anion appears as part of the R substituent; the product appears as the trlethyl ammonium salt. 2 This compound is not strictly an aciylamide but rather N -R -2-(3-amino5-NR R -fi-halopyrazhloyloxy) benzarnlde.

PREPARATION OF PYRAZINAMIDES Example 41 amino-6-chyoropyrazinamide, which melts at 205-206 C. Analysis.Calcd for C7H1QC1N5O (percent): C, 38.98;

H, 4.67; N, 32.48. Found (percent): C, 38.65; H, 4.60;

Example 42 N ethoxycarbonylmethyl 3,5 diamino 6 chloropyrazinamide.Ethyl glycinate hydrochloride (5.60 g.,

0.04 mole) is dissolved in a mixture of water (50 ml.) and sodium bicarbonate (5.0 g., 0.06 mole). A solution of N (t butyl) 3 methyl 3 (3,5 diamino 6- chloropyrazinoyloxy)acrylamide (3.27 g., 0.01 mole) in tetrahydrofuran ml.) is added and the mixture 1 1 warmed on the steam bath for two hours. Water (500 ml.) is added and the solution chilled. The solid which precipitates is collected and dried, 2.17 g. (80%), M.P. 172-4 C. After purification is effected by recrystallization from isopropyl alcohol the N-ethoxycarbonylmethyll2 Analysis.Calcd for C H ClN O (percent): C, 43.93; H, 5.70; N, 27.95. Found (percent): C, 44.22; H, 5.68; N, 27.84.

Example 44 o N -phenyl-3 S-diamino-6-chloropyrazinamide.-A mix- 3,5-d1am1no-6-chloropyraz1nam1de melts at 174-175 C. A-nalysis.Calcd for C H ClN O (pecent): c, 39.49; gig ggg gg ggg gf gi ggi g g g 3:29 mm (Percent): 39'77; 4'38; (4.65 g., 0.05 mole) and n-amyhalcohol (20 ml.) is Employing substantially the method as described in Exgi to g gf' 3 l i Solutlon 1S reflilxedl i ample 42, but substituting for the ethyl glycinate hydro- 1O g tare. w 1 e redmove g g u e chloride used therein, an equivalent amount of aminoso 1 ig 1s gl f p i i use g acetonitrile hydrogen sulfate or methyl glycerinate hyt fii q y Iss0 z 2 g drochloride or propyl glycinate hydrochloride there is t 3 extrache i k y 83 produced N-cyanomethyl-3,5 -diamino-6-chloropyrazin- 15 d m portlon.s)t am 18 amide, N methoxycarbonylmethyl-3,5-diamino-6-chloroa r0515 magneslunh Su t t pyrazinamide or N-propoxycarbonylmethyl-3,S-diaminoun er re preissure' e resl He Is i Wlt 6 chloropyrazinamide respectively butyl chloride to give 0.30 g. of N-phenyl-3,5-d1am1no-6- chloropyrazinamide, M.P. 193-7" C. Recrystallization Ex 16 43 from cyclohexane gives material melting at 198-202 C. amp 20 Analysis.Calcd for C H ClN O (percent): 0, N-(Z-morpholinoethyl)-3,5-diamino 6 chloropyrazin- 50.10; H, 3.82; N, 26.56. Found (percent): C, 49.98; H, amide.-A solution of N-(t-butyl) 3 methyl-3-(3,5-di- 3.84; N, 26.39. amino-6-chloropyrazinoyloxy)acrylamine (3.27 g., 0.01 Employing substantially the methods as described in mole) and Z-morpholinoethylamine (1.50 g., 0.0115 Examples 41, 43 and 44, but substituting for the n-(tmole), in tetrahydrofuran is refluxed for 2 hours. The butyl)-3-methyl-3-(3,5 diamino-6-chloropyrazinoyloxy) tetrahydrofuran is removed under reduced pressure and acrylamide and the amines used therein, equivalent the residue is suspended in hexane ml.) and filtered, amounts of N-R -2-R -3-R -3-(3-amino-5-NR R -6-halo- 3.0 g. (100%), M.P. 153-66 C. Recrystallization of the pyrazinoyloxy)acrylamide and H NR respectively which N-(2-morpholinoethyl)-3,5-diamino 6 chloropyrazinare described in Table III, there are produced the N-R -3- amide from absolute ethanol gives material melting at 30 amino-5-NR R -6-halo-pyrazinamides, also described in 178-80 C. Table III.

TABLE III 1 NH I I 2 RLNHZ R: l )YNHQ halo CO-C=O-CONHR hl C N N u N O H R o R R Example R R R3 R4 R R6 halo H H CH3- H (CHahC- 0H5 Cl N-(CH2)2 I1-C3H7 46 H H H CH OHr- CH OOHzCH I 47 H E Q E (CHa)aC- Br 48 CH2=CH-CHZ- H OH=CHCH=OH- CH;- ogmmcfim- 01 49 HCEC-OHz- H OH; H oHmo- N 01 l NH(CHz)2- -N 50 3 H Same ..H Same 01 N-(CII2)g- 51 H I H CHaCHr- Cl D CHz GOQSQ (CHz)2 52.4.. (CHa)zN(CH-z)z H ou H (0H3)3c- C 01 N--(CHz)r- 53 HOCHzCH H Same H S 1 2 ame OH3 N(CH2)2- Cl 54 H00H2(oH0H),oH2- H GH=OHOH=CH 0113- Q Cl omoflf- H H 01 CH C- 13 14 TABLE III.Cntinued Example R R R R R R halo 56 H CH3- H Same 01 CH CH3- 57 F H H CHaCHT- Cl C11 0 0 8 CH2 58 WOW CHZ H CH3- H (CH )3C-- CH CHr Cl 59 (HQ H CH=CH-CH=CH CH CH =CHCH Cl (CH C- CHECCHr- 01 Same Cl -(CH2)4'' .d0 CHQCHZ- C1 d0 CzH5OCHzCHz- Cl d0 i-C3H7OCHzCHr 01 do Cl PREPARATION OF PYRAZINOIC ACID HYDRAZIDES Example 67 3,5-diamino 6 chloropyrazinoic acid, 2,2-tetramethylenehydrazide.A mixture of l-aminopyrrolidine (2.15 g., 0.025 mole), N-(t-butyl)-3-methyl-3-(3,5-diamino-6- chloropyrazinoyloxy)acrylamide (6.56 g., 0.02 mole) and acetonitrile (100 ml.) is heated under reflux for 2 hours. The solid which separates is collected and dried, 3.45 g. (67% M.P. 2224.5 C. Recrystallization from acetonitrile gives 3,S-diamino-6-chloropyrazinoic acid, 2,2-tetramethylenehydrazide, M.P. 2245.5 C.

Analysis.Calcd for C H CIN O (percent): C, 42.11; H, 5.10; N, 32.74. Found (percent): C, 42.44; H, 4.88; N, 32.38.

Example 68 3,5-diamino 6 chloropyrazinoic acid, 2-(2-pyridyl) hydrazide.--A mixture of 2-hydrazinopyridine (2.18 g., 0.02 mole), N-(t-butyl)-3-methyl-3-(3,5-diarnino-6-chloropyrazinoyloxy)acrylamide (3.39 g., 0.01 mole) and acetonitrile (75 ml.) is heated under reflux for 3 hours. The solid that separates is collected and dried, 2.21 g. (79% M.P. 283-6 C. dec. This sample is further purified by dissolving in dilute methanesulfonic acid and reprecipitating by the addition of sodium hydroxide solution to give 3,5-diamino-6-chloropyrazinoic acid, 2- (2-pyridyl)hydrazide, M.P. 286-90 C. dec.

Analysis.-Calcd for C H ClN O (percent): C, 42.94; H, 3.60; N, 35.06. Found (percent): C, 42.75; H, 3.96; N, 34.75.

Example 69 3,S-diamino-6-chloropyrazinoic acid, 2-(2-pyri1nidinyl)- hydrazide hydrate.A mixture of 3,5-diamino-6-chloropyrazinoic acid (1.90 g., 0.01 mole) and triethylamine (1.0 g., 0.01 mole) in dimethylformamide ml.) is stirred for 10 minutes. To this solution is added N-(t-butyl)-5-methy1isoxazolium perchlorate (2.40 g., 0.01 mole) and the resulting solution is stirred for one hour. A solution of 2-hydrazinopyrimidine (4.40 g., 0.04 mole) in dimethylformamide (20 ml.) is added, the solution is stirred 4 hours then warmed on the steam bath for 3 hours. Water (200 ml.) is added and the solid which separates is collected and dried. The yield is 2.25 g. (80.5%);

-...do H do N CH M.P. 257-260 C. Recrystallization from acetonitrile gives light tan crystals, M.P. 2623 C. of 3,5-diamino-6- chloropyrazinoic acid, 2-(Z-pyrimidinyDhydrazide hydrate.

Analysis.-Calcd for C H CIN O-H O (percent): C, 36.19; H, 3.71; N, 37.52. Found (percent): C, 36.18; H, 3.75; N, 37.74.

Example 70 3,5-diamino 6 chloropyrazinoic acid, 2,2-hexamethylenehydrazide.A solution of l-aminohomopiperidine (4.56 g., 0.04 mole) and N-(t-butyD-3-methyl-3-(3,5-di amino-6-chloropyrazinoyloxy)acrylamide (3.28 g., 0.01 mole) in tetrahydrofuran (50 ml.) is refluxed for 24 hours. The solvent is removed under reduced pressure and the residual oil is dissolved in isopropyl alcohol ml.). The solid which separates on cooling is collected and dried, 1.06 g., (37%) M.P. 181-90 C. Recrystallization from acetonitrile gives 3,S-diamino-6-chloropyrazinoic acid, 2,2-hexamethylenehydrazide, melting at -192 C.

Arzalysis.Calcd for C H CIN O (percent): C, 46.39; H, 6.02; N, 29.52. Found (percent): C, 46.80; H, 5.85; N, 29.96.

EXAMPLE 71 3,S-diamino-6-chloropyrazinoic acid, 2,2-pentamethylenehydrazide.A mixture of 3,5-diamino-6-chloropyrazinoic acid (3.80 g., 0.02 mole) and triethylamine (2.0 g., 0.02 mole) in dimethylformamide (40 ml.) is stirred for 10 minutes. To this solution is added N-(t-butyl)-5- methylisoxazolium perchlorate (4.80 g., 0.02 mole) and the resulting solution is stirred for one hour. I-aminopiperidine (5.2 g., 0.052 mole) is added and the solution is warmed on the steam bath for four hours. Isopropyl alcohol (250 ml.) is added and the solid which separates on cooling is collected and dried, 2.22 g. (41%), M.P. 238-43" C. Recrystallization from acetonitrile gives yellow crystals of 3,S-diamino-6-chloropyrazinoic acid, 2,2- pentamethylenehydrazide, M.P. 244-45 C.

Analysis.Calcd for C H ClN O (percent): C, 44.36; H, 5.59; N, 31.05. Found (percent): C, 44.52; H, 5.28; N, 31.37.

Example 72 3,5-diamino-4-(3,5-diamino 6 chloropyrazinarnido) 4H-l,2,4-triazo1e hemihydrate.A mixture of 3,5-diamino-6-chloropyrazinoic acid (1.90 g., 0.01 mole) and triethylamine (1.0 g., 0.01 mole) in dimethylformamide (20 ml.) is stirred for 10 minutes. To this solution is added N-(t-butyl)--methylisoxazolium perchlorate (2.40 g., 0.01 mole) and the resulting solution is stirred for one hour. A mixture of 3,4,5-triamino4H-1,2,4-triazole (3.06 g., 0.03 mole) and dimethylformamide m1.) is added and the reaction mixture is warmed on the steam bath for 16 hours. Water (200 ml.) is added and the solid which precipitates is collected and dried; yield 1.50 g. (51%), gradual decomposition over 200 C. Recrystallization from water gives brown crystals of 3,5-diamino-4- (3,5-diamino 6 chloropyrazinamido)-4H-1,2,4-triazole hemihydrate, M.P. 275-8 C., dec.

Analysis.-Calcd for C7H9ClN10O' /2H2O (percent): C, 28.63; H, 3.43; N, 47.70. Found (percent): C, 28.58; H, 3.37; N, 47.45.

Employing substantially the process as described in Examples 67, 68 and 70 but substituting for the l-arninopyrrolidine, Z-hydrazinopyridine and 1-aminohomopiperidine respectively and the N-(t-butyl)-3-methyl-3-(3,5-diamino 6 chloropyrazinoyloxy)acrylamide used therein equivalent amounts of the NH -R and N-R -2-R -3-R -3- (3-amino-5-NR R -6-halopyrazinoyl0xy)acrylamide, identified in Table IV there are produced the 3-amino-5- NR R -6-halopyrazinoic acid, hydrazides also described in Table IV.

16 PREPARATION OF PYRAZINOYLAMIDINES Example 83 N (3,5-diamino 6-chloropyrazinoyl)benzamidine- Sodium hydroxide (1.20 g., 0.03 mole) is dissolved in Water ml.) and benzamidine hydrochloride (5.60 g., 0.036 mole) is added. This solution is stirred two minutes, N-(t-butyl)-3 methyl 3 (3,5-diamino-6-chloropyrazinoyloxy)acrylamide (3.28 g., 0.01 mole) is added and the mixture stirred for 2 hours. The solid is collected, dried and recrystallized from acetonitrile to give 0.83 g. (29%), M.P. 220-4 C. dec. Recrystallization from ethanol-acetonitrile gives N-(3,5-diamino 6 chloropyrazinoyl)benzamidine, M.P. 221-224 C. dec.

Analysis.-Calcd for C H ClNgO (percent): C, 49.57; H, 3.81; N, 28.91. Found (percent): C, 49.95; H, 3.90; N, 29.12.

Employing substantially the same procedure as described in Example 83, but substituting for the benzamidine hydrochloride employed therein, an equivalent amount of p-chlorobenzamidine hydrochloride, acetamidine hydrochloride valeramidine hydrochloride, p-methylbenzamidine, hydrochloride or m-ethoxybenzamidine hydrochloride there is produced N-(3,5 diamino-6-chloropyrazin- TABLE IV N -NHz N NH2 R HzNR R hal C-OC=CCONHR hal CONH-R' N I] N O R R R R R R R R halo Example:

73 H H CH H (CH3)3C NHr- Cl 74 CH3- CHr- CH H Same (CHa)zN- Cl.

75 C2H5- H CH H ...(l0 N-- Cl I 76 H H ms-Q H oHaorn- 1 j 71 H E Q- H onmo- N- Br 78 CH2=CH-OH2 H --CH=CHCH=CH- CHa- N- CI 79 HCEC-CHF I-I OH H (CH C Same as above 01 NH: ==K 80 H Sameasabove H Same llI N Cl 1 s1 -om- 11 ms-Q H CHaCH2 o N o1 82 H H CH3- H (CH C Cl -U m HM IOU-:1 m w m moa #0 Hm m w HH lowll: m wofi 5 E EOO EHOV m :32... m A 6 m Eo mo mo m 8 m I A8 6 m REUOV ou m m 6 lnfimovl m 18...: m 2:5 3 05am QHOIOMOHH do MHWUI Mn lwaww m IXNHIHOVI 6 mo z omov m oEo Ma 6 IE0 lmoflmolmoflmol @lo 8 HO Lmol :oafiw m G wm -U IORQHHUV m LHnO FO mm NHHOI 6 g m Lao PH 6 m AU m 5 6 m mo OA EOV M M mo mo mm #0 m MONHONNOI. IGHHO HHO HHO HHO WO m Z VN .iilllillda HO mm m m m Lm Nm m 5 cm 6 HH o O QmOv m m Q V Q V 5w "2952mm 2 5H M M "M .m a z w J z z z o mzoo fl/ 22 m E mz w o oooo m mooo E m a N am Swaz Z\ O MHZ SHZ Z\ z z z 3H 5H 17 oyl)-p-chlorobenzamidine, N-(3,5 diamino 6 chloropyrazinoyl)acetamidine, N-(3,5 diamino 6 chloropyrazinoyl)valeramidine, N 3,5 diamino-6-chloropyrazinoyl) p methylbenzamidine, and N(3,5-diamino6- chloropyrazinoyl) m ethoxybenzarnidine respectively.

PREPARATION OF PYRAZINOYLGUANIDINES Example 84 (3.5 diamino 6 chloropyrazinoyl)guanidine hydrochloride dihydrate.-A mixture of 3,5-diamino-6-chloropyrazinoic acid (1.90 g., 0.01 mole) and triethylamine (1.0 g., 0.01 mole) in dimethylformamide (20 ml.) is stirred for 10 minutes N-(t-butyl)--methylisoxazolium perchlorate (2.40 g., 0.01 mole) is added and the resulting solution is stirred for 1 hour.

Sodium (1.15 g., 0.05 mole) is dissolved in absolute ethanol (50 ml.). Guanidine hydrochloride (4.75 g., 0.05 mole) is added and the mixture stirred for one-half hour. The mixture is filtered and the filtrate evaporated under reduced pressure. The residue is dissolved in dimethylformamide ml.) and added to the above solution. This reaction mixture is stirred for 24 hours, poured into water (100 ml.) and chilled. The solid which separates is collected and dried. The yield is 0.88 g., M.P. 229-233 C. dec.

The product is dissolved in a mixture of water ml.) and methanesulfonic acid (2 ml.) by Warming, concentrated hydrochloric acid (4 ml.) is added, and the solution allowed to stand. The solid which precipitates is collected and dried. The yield of (3,5-diamino-6-chloropyrazinoyl)guanidine hydrochloride dihydrate is 36%, M.P. 295 C. (dec.). This material exhibits identical chromatographic behavior, infrared spectra and shows no mixed melting point depression with a sample prepared by another method.

Example 85 3,5 diamino 6 chloropyrazinoylguanidine hydrochloride dihydrate.Sodium (0.09 g., 0.004 mole) is dissolved in absolute ethanol (10 ml.) and guanidine hydrochloride (0.382 g., 0.004 mole) is added. This mixture is stirred one half hour, N-(t-butyl)-3-methyl-3(3,5-diamino 6 chloropyrazinoyloxy)acrylamide (0.300 g., 0.0009 mole) is added and the mixture is refluxed for one hour. The reaction mixture is cooled, diluted with water (25 ml.) and acidified with dilute hydrochloric acid. The solid which separates on standing is collected and dried to yield 0.15 g. (60%) of (3,S-diamino-6-chloropyrazin oyl)guanidine hydrochloride dihydrate, M.P. 295 C. (dec.).

Example 86 1 (3,5 diamino 6 chloropyrazinoyl) 3 isopropylideneaminoguanidine-A mixture of 3,5-diamino-6- ohloropyrazinoic acid (3.80 g., 0.02 mole) and triethylamine (2.0 g., 0.02 mole) in dimethylformamide (40 ml.) is stirred for 10 minutes. To this solution is added N (t butyl) 5 methylisoxazolium perchlorate (4.80 g., 0.02 mole) and the resulting solution is stirred for one hour. A solution of isopropylideneaminoguanidine (9.12 g., 0.08 mole) in dimethylformamide ml.) is added and the reaction mixture is stirred at room temperature for 18 hours. Water (250 ml.) is added and the solid which precipitates is collected and dried. The yield of 1- (3,5-diamino 6 chloropyrazinoyl) 3 isopropylideneaminoguanidine is 4.35 g. (76%); M.P. 171-8 C. Recrystallization from acetonitrile gives light yellow crystals, M.P. 183-6" C.

18 Analysis.-Calcd for C H CIN O (percent): C, 37.96; H, 4.60; N, 39.36. Found (percent): C, 38.01; H, 4.65; N, 39.15.

Example 87 1 (3,5 diamino 6 chloropyrazinoyl)-3-hydroxyguanidine.--Sodium (1.0 g., 0.044 mole) is dissolved in refluxing isopropyl alcohol (200 ml.). Hydroxyguanidine sulfate hydrate (6.38 g., 0.024 mole) is added and this mixture is refluxed for one hour. N-(t-butyl)-3-methyl-3- (3 ,5 -diamino-6-chloropyrazinoyloxy) acrylamide (6.54 g., 0.02 mole) is added, refluxing is continued for one hour, and then the mixture is cooled and filtered. The yellow solid is washed with water and isopropyl alcohol and dried to give 2.75 g. (56%) of 1-(3,5-diamino-6-chloropyrazinoyl)-3-hydroxyguanidine, M.P. 188-200 C. (effervescense). Recrystallization from dimethylformamide-Water gives material melting at 200-202" C. (dec.).

Analysis Calcd for C H ClN O (percent): C, 29.34; H, 3.28; N, 39.92. Found (percent): C, 29.42; H, 3.25; N, 40.01.

Example 88 1 (3,5 diamino 6 chloropyrazinoyl) -3 benzyloxyguanidine.A solution of N-(t-butyl)-3-methyl-3- (3,5-diamino-6-chloropyrazinoyloxy) acrylamide 1.08 g., 0.0033 mole) and benzyloxyguanidine (1.1 g., 0.0067 mole) in tetrahydrofuran (30 ml.) is refluxed for 48 hours. The solvent is removed under reduced pressure and isopropyl alcohol (20 ml.) is added to the residue. The solid present is collected and dried, 0.95 g., M.P. -l10 C., resolidifies, and remelts about C. Recrystallization from benzene gives light yellow crystals of 1-(3,S-diamino-6-chloropyrazinoyl) 3 benzyloxy guanidine, M.P. l636 C.

*Calcd for C13H14ClN7O2 (percent): C, 46.50; H, 4.20; N, 29.21. Found (percent): C, 46.72; H, 4.23; N, 29.45.

Employing the process described in Examples 84 and 86 but substituting for the pyrazinoic acid, the isoxazolium salt and the guanidine used therein equivalent amounts of 3-amino-5-NR R -6-halopyrazinoic acid, N-R -5-R -4-R isoxazolium salt and a guanidine represented by solved in refluxing isopropyl alcohol (100 ml.). 1,3-diaminoguanidine hydroiodide (5.25 g., 0.024 mole) is added and the reaction mixture is refluxed for one hour. N (t butyl)-3-methyl-3-(3,5-diamino-6-chloropyrazinoyloxy)acrylamide (3.27 g., 0.01 mole) is added and the mixture is refluxed for one hour. The yellow solid which separates is collected, washed With Water, and dried, 1.94 g. (70%), M.P. gradual decomposition With elfervesence over 185 C. This sample is purified by dissolving in dilute hydrochloric acid and reprecipitating by the addition of concentrated ammonium hydroxide solution, to give 1- (3,5 diamino 6-chloropyrazinamido)-3-aminoguanidine hydrate, M.P. 196-200 C. with effervescence.

Analysis.Calcd for C H ClN O-H O (percent): C, 25.95; H, 4.36; N, 45.40. Found (percent): C, 26.17; H, 4.44; N, 45.87.

Example 124 1-(3,5-diamino-6-chloropyrazinamido) 2,3 ethyleneguanidine.Employing the procedure substantially as described in Example 123 but substituting for the 1,3-diaminoguanidine hydroiodide used therein an equivalent amount of 2-hydrazino-2-imidazoline hydroiodide, there is produced 1-(3,5-diamino 6 chloropyrazinamido)-2,3- ethyleneguanidine, M.P. 2501 C. (dec.).

Analysis.Calcd for C H CIN O (percent): C, 35.49; H, 4.10. Found (percent): C, 35.36; H, 4.17.

Employing the method substantially as described in Examples 121 and 123 but substituting for the pyrazinoic acid or pyrazinoyloxyacrylamide and the aminoguanidines used therein, equivalent amounts of 3-amino-5-NR R -6 halopyrazinoic acid or N-R -2-R -3-R -3-(3-amino-5- NR R -6-halopyrazinoyloxy)acrylamide and 1-amino-2- R -3-R -3-R -guanidine described in Table VI, there are produced the 1- 3-amino-5-NR R -6-halopyrazinamido 2-R -3-R -3-R -guanidines also described in Table VI.

24 tion of sodium (0.23 g., 0.01 mole) in isopropyl alcohol ml.) and this mixture is refluxed with stirring for one-half hour. N-(t-butyl)-3-(3,5-diamino-6-chloropyrazinecarbonyloxy)crotonamide 3.27 g., 0.01 mole) is added and the reaction mixture is refluxed an additional hour.

The yellow solid is filtered from the hot solution, dissolved in water (100 ml.) and filtered. The filtrate is acidified With dilute hydrochloric acid and the solid that separates is collected and dried. The yield of N-cyano-3,5-diamino- 6-chloropyrazinecarboxamide is 1.50 g. (71% M.P. 330 C Purification is effected by recrystallization from nitromethane.

Analysis.-Calcd for C H ClN O (percent): C, 33.89;

H, 2.37; N, 39.53. Found (percent): C, 33.94; H, 2.50; N, 39.48.

Example 133 1-(3,5-diamino-6-chloropyrazinoyl) 5 benzyloxybiguanide.-A mixture of N-t-butyl-3-methyl-3-(3,5-diamino-6-chloropyrazinecarbonyloxy)acrylamide (3.27 g., 0.01 mole) and l-benzyloxybiguanide (3.30 g., 0.016 mole) in tetrahydrofuran (90 ml.) is refluxed for 24 hours. The tetrahydrofuran is removed under reduced pressure and the residue is washed out With isopropyl alcohol to yield 2.9 g., M.P. ISO-191 C. Recrystallization from acetom'trile gives 1-(3,5-diamino-6-chloropyrazinoyl)-5-benzyloxybiguanide, M.P. 198-199 C.

Analysis.-Calcd for C H CIN O (percent): C, 44.50; H, 4.27; N, 33.37. Found (percent): C, 44.68; H, 4.32; N, 33.90.

Employing the procedure of Example 133 but substituting for the l-benzyloxybiguanide and the N-t-butyl-3- methyl-3-( 3,5-diamino 6 chloropyrazinecarbonyloxy) acrylamide' utilized therein, substantially equivalent amounts of the N-t-butyl 3 methyl 3 (3-amino-5- NR R -6-chloropyrazinecarbonyloxy)acrylamides and the TABLE VI R1 N-R R1 N NH; it \N NHz HzN-NH- N balm GOOG=CCONHR5 hal OONHNH-CN N l N R: R4 R12 R R2 R3 R4 R5 R11 R12 R13 11810 Example CH3- oH CH3- H (CHQaO-JI -GH3 H 01 126 H Same H Same H OHZCH2OH H 01 121 orsom- H Q- H do H G H or 12s H H CH3- H ..-do oHaoH. H 01 129 H H Same H do n-C H -H H 01 130 H H do H do- -o.H1-n H 01 131 H H .....de H do H CHOHz- H 01 Example 132 N cyano-3,S-diamino-6-chloropyrazinecarboxamide.

substituted biguanides described in Table VII there are produced the 1-(3-amino-5-NR R -6-chloropyrazinoyl)-5- Cyanamide (0.50 g., 0.012 mole) is added to a hot solu- 75 substituted biguanide s also described in Table VII.

R TABLE VI:

\N /N NH IFIH IHIH 1 HzN-G-NH-C-NHOR" R2 9 c1 C--O-C=CH-CONHC(CHa)a N NH: NE NH R2 II ll 01 CNHCNHC-NHOR" Starting material from example number R1 Rfl u Example:

134 27 H -CHz-OH(CH;)

135 29 (CH3)2N(CH2)2-H --CHr-CH 136 3o H0(CHz)z H CHz-Br 131 as Q-om H CH2-Cl N-(2-thiazolin-2-y1)-3,5-diamino-6 chloropyrazinecarboxamide hydrochloride hemihydrate.-A mixture of 2- amino-Z-thiazoline (4.08 -g., 0.04 mole), N-(t-butyl)-3- methyl 3 (3,S-diamino-6-chloropyrazinecarbony1oxy) acrylamide (3.27 g., 0.01 mole) and tetrahydrofuran (70 ml.) is heated under reflux for 24 hours. The reaction mixture is chilled and a small amount of insoluble material is filtered ofi and discarded. The filtrate is evaporated to dryness and the residue is dissolved in water (50 ml.) by the addition of dilute methanesulfonic acid (6 N, 1.5 ml.). Concentrated hydrochloric acid (5 ml.) is added and the mixture set aside until crystallization appears complete. The solid is collected and dried, 0.86 g. (27%), M.P. 340 C. Recrystallization from aqueous ethanol gives 40 the N (2 thiazolin-Z-yl)-3,5-diamino-6-chloropyrazine- TABLE VIII 27 28 Example 151 TABLE IX-Continued N (2 pyridyl) 3-amino-S-dimethylamino-6 chlro- 1 2 R6 M.P.,C, pyrazinecarboxamide.-A mixture of sodium hydride (1.72 g., 0.04 mole, 56% in mineral oil) and 2-amin0- 153 H H L 300 pyridine (3.76 g., 0.04 mole) in tetrahydrofuran (200 5 ml.) is stirred at room temperature until hydrogen evolu- L tion ceases. N-(t-butyl)-3-rnethyl-3-(3-amino-5-dimethyls amino-6-chloropyrazinecarbonyloxy)acrylamide 7.06 g., 0.02 mole) is added and this mixture stirred for 24 hours. 154 N H H L CH3 237 238 The reaction mixture is diluted with water (500 ml.) 0 and extracted with ethyl acetate (3x 200 ml.). The ethyl s acetate is removed under reduced pressure and the oily residue is dissolved in acetonitrile (75 ml.) and diluted 155 186489 with water (125 ml.). The yellow solid that separates is L collected, Washed with Water, and dried, 1.52 g., M.P. ISO-136 C. Recrystallization from acetonitrile does not N change the melting point.

Analysis.-Calcd for C H ClN ClN O (percent): 0, 156 H H :N 1 49.23; H, 4.48; N, 28.71. Found (percent): C, 49.33; H, l Decomposition.

Employing the procedure of Example 151 but substituting for the Z-aminopyridine and N-t-butyl-3-methyl-3-(3- amino-S-dimethylamino 6 chloropyrazinecarbonyloxy) acrylamide utilized therein the amine H NR and N-tbutyl 3 methyl-3-(3-amino-5-NR R -fi-chloropyrazinecarbonyloxy)acrylamide described in Table IX there are produced the correspondingly N-substituted 3 amino-5- NR R 6 chloropyrazinecarboxamides also described in Example 157 Table IX.

TABLE IX (3,5-diamino-6-chloropyrazinoyl)sulfamide.To a mixture of sulfamide (0.22 mole) and triethylamine (0.44 N rnole) in acetonitrile (150 ml.) is added in one portion N NH2 HZNRQl N (t butyl) 3 methyl 3 (3,5 diamino 6 -1 chlo- 112 ropyrazinoyloxy)acrylamide (0.2 mole) with stirring at 01 F? C=CH CONHC(CH3) ambient temperature. After about minutes, the result- 0 CH3 ing solution is diluted with ice Water (250 .ml.) and N neutralized with acetic acid and the solid which separates N NH; is collected and dried giving (3,5-diamino-6-chloropyr- I azinoyl)sulfamide, M.P. 193.s 194.s c.

01 fi The above procedure can be employed to prepare other 0 pyrazinoylsulfamide products as illustrated by those de- R1 R2 R6 MP 00 scribed in the following table. The pyrazinoyloxyacryl- 45 amide identified in Table X is substituted for that emiggff H H 23mm ployed in Example 157 above and is reacted with the I I sulfamide also identified in Table X to provide the desired pyrazinoylsulfamide having the R R R R and halo S substituents identified in Table X.

TABLE X R 31 N /N\ NH; N %N\ NH: Rm R I H N--SOgNR R RZ/ I halo 0 0z-C=CC ONHRB halo 0 O-NH-S OZN N IV R; R4 III R20 R R2 halo R R R R R Example No.

158 CHEC-CHz- H C1 0113- H (0H3)3c H H 159 0112:011-011? H 01 H=OHCH=CH C 3 H H l 160 H I ms-Q H mm- CHz- H 161 H H Br CaHa- H s)aC-' Same CHa 162 H H 01 CH3- H Same H H I 163 -Oflk- H or ms-Q H C2H5- H H l2%::"":: tl fifi ii 8 same $3552 5... ii it 166-- HO-CHflCHOI-IMCHr- H (:1 CH=CHCH=CH CH3- H H 167 HaocHr- H 01 C6H5- H (CH3)3C H H 168 CoH5CH2- H Cl CH3 H Same CBH5CH2 H TABLE XIContinued Method of R R R R" example No. M P.( C

192 H H CH1CONH H 43 CHa-N N( H1):

193 H H (OHg);l lI(CHz)z- 43 193a H H (3H3 H 68 262-264 1 Decomposition.

As mentioned previously, the compounds prepared by Example 194 the process of this invention are useful diuretic and natriuretic agents. Because of the diversity of the compounds, although all are amide derivatives, they naturally present varying degrees of diuretic activity but within the dose limits mentioned below. They difier from most of the known, effective diuretic agents in that the compounds of this invention selectively enhance the excretion of sodium ions without causing an increase in excretion of potassium ions. The potassium ion loss, which is caused by known diuretics, often results in a severe muscular weakness. Since the compounds of this invention are essentially free of this potassium depletion, they have this decided advantage as diuretics. As diuretic agents, they can be used for the treatment of edema, hyper-tension and other diseases known to be responsive to this therapy.

It has also been found as another feature of this invention that when coadministered with other diuretic agents known to enhance the elimination of potassium ions along with sodium ions, the novel compounds will reduce the excretion of potassium ions and thus overcome this undesirable property of the other diuretic agents. The compounds of this invention, therefore, are useful in combination with other classes of diuretic agents in order to prevent the elimination of potassium ions which otherwise would be promoted by the other diuretics. In addition, the compounds of this invention are useful by themselves as diuretic and/ or saluretic agents.

In some instances, it may be desirable to use a salt of these compounds, employing a pharmaceutically acceptable acid, and these salts are to be considered as included in this invention and in the scope of the claims.

The products of this invention can be administered to man or animals in the form of pills, tablets, capsules, elixirs, injectable preparations and the like and can comprise the only essential active ingredient of the pharmaceutical formulation or, as mentioned above, they can be combined in pharmaceutical formulations with other diuretic agents or, indeed, other therapeutic agents.

The compounds of this invention are advantageously administered at a dosage range of from about 5 mg./day to about 1000 mg./day or at a somewhat higher or lower dosage at the physicians discretion, preferably in subdivided amounts on a one to four times a day regimen.

The class of compounds which can be designated as pyrazinoylhydrazides generally do not spare potassium excretion to the same extent as the other compounds of this invention, but their diuretic and natriuretic activity is of approximately the same order, the effective dose being in the range of 5 mg./day to about 1000 mg./day.

The actual dose required of any of the products of the process of this invention depends on the degree of activity of the particular compound, the age, physical condition and seriousness of the disorder being treated and must be determined by the practitioner administering the active agent.

Dry filled capsule containing 10 mg. of active ingredient Per capsule, mg. 1 (3,5 diamino 6 chloropyrazinoyl)-3-hydroxyguanidine (from Example 87) 10 Lactose 313 Magnesium stearate 2 Mixed powders 325 Mix the 3,5 diamino 6-chloropyrazinoyl)-guanidine hydrochloride, from Example 84, lactose, and magnesium stearate and reduce to a No. 60 mesh powder. Encapsulate, filling 325 mg. in each No. 2 capsule.

Example Combination dosage form in dry filled capsule Per capsule, mg. 1 (3,5 diamino 6-chloropyrazinoyl)-3-benzyloxy guanidine (from Example 88) 15 Hydrochlorothiazide 50 Magnesium stearate 2 Lactose 258 Mixed powders 325 Mix all of the above ingredients, reduce to a No. 60 mesh powder and encapsulate, filling 325 mg. in each No. 2 capsule.

Example 196 Mix the (3,5-diamino 6 chloropyrazinamido) guanidine, lactose, and magnesium stearate and reduce to a No. 60 mesh powder. Encapsulate, filling 275 mg. in each No. 2 capsule.

Example 197 Dry filled capsule containing 50 mg. of active ingredient Per capsule, mg. N-(3,5-diamino 6 chloropyrazinoyl)benzamidine from Example 83) 50 Lactose 273 Magnesium stearate 2 Mixed powders 325 the N-(3,5-diamino-6-chloropyrazinoyDbenzamidme, lactose, and magnesium stearate and reduce to a No. 60 mesh powder. Encapsulate, filling 325 mg. in each No. 2 capsule.

Example 198 146) 100 Lactose 223 Magnesium stearate 2 Mixed powders 325 Mix all of the above ingredients, reduce to a No. 60 mesh powder and encapsulate, filling 325 mg. in each No. 2 capsule.

Example 199 Dry filled capsule containing 50 mg. of active ingredient Per capsule, mg. 3,S-diamino-6-chloropyrazinoic acid 2-(2-quinolinyl) hydrazide (from Example 82) 50 Lactose 273 Magnesium stearate 2 Mixed powders 325 Mix all of the above ingredients, reduce to a No. 60 mesh powder and encapsulate, filling 325 mg. in each No. 2 capsule.

What is claimed is:

1. A process for the preparation of a compound of structural formula which comprises the reaction of a compound of structural formula N N NH; a

halo \N (HJOCII=(E-CONHR5 with a compound of structural formula HN--R R wherein R is a member selected from the group consisting of 1 hydrogen, (2) lower alkyl, (3) lower alkenyl, (4) lower alkynyl, (5 C cycloalkyl, (6) C cycloalkyl-lower alkyl (7) di(lower alkyl)amino-lower alkyl, (8) hydroxy-lower alkylmethyl, (9) polyhydroxy-lower alkylmethyl, (10) w,w,w-t1lflu0IO-1OW61' alkyl, (11) phenyl-lower alkyl, (12) halophenyl-lower alkyl, (13) furyl-lower alkyl, (14) phenyl, 15 halophenyl, (16) lower alkoxy, and (17) amino; R is a member selected from the group consisting of 1) hydrogen, and (2) lower alkyl; R and R when each represents lower alkyl, can be linked together to form an azacyclic structure with the nitrogen atom to which they are attached;

34 R is a member selected from the group consisting of (1) lower alkyl, (2) phenyl, and

R is a member selected from the group consisting of (1) hydrogen, (2) a hydrocarbon radical which when linked with R forms an o-phenylene group with the carbons to which R and R are attached; halo is a member selected from the group consisting of (1) chloro, (2) bromo; and (3) iodo;

R is a member selected from the group consisting of 1) lower alkyl,

( 2) mono (lower alkoxy)methyl-lower alkyl,

(3) di(lower alkoxy)methyl-lower alkyl,

(4) cyano-lower alkyl,

(5) lower alkoxycarbonyl-lower alkyl,

(6) phenyl-lower alkyl,

(7) guanidinocarbonyl-lower alkyl,

(8) guanidinoaminocarbonyl-lower alkyl,

(9) heterocyclic-lower alkyl-aminocarbonyl lower alkyl, wherein the heterocycle is linked through a nuclear nitrogen atom and contains up to 1 other nuclear hetero atom selected from oxygen and nitrogen, which when nitrogen is substituted with hydrogen or lower alkyl,

(10) di(lower alkyl)aminomethyl-lower alkyl,

(11) 2-(2-imidazolinyl)aminomethyl-lower alkyl,

(12) heterocyclic-lower alkyl wherein the heterocycle is of 5 to about 8 nuclear members containing up to 2 heteroatoms selected from the oxygen and nitrogen, either unsubstituted or substituted with lower alkyl,

(13) lower alkenyl,

(14) lower alkynyl,

(15) phenyl,

(16) halophenyl,

(17) lower alkyl-phenyl,

(18) lower alkoxy-phenyl,

(19) cyano,

(20) amino,

(21) di(lower alkyl)arnino,

(22) (phenyl-lower alkyl) (lower alkyl)amino,

(23) pyridylamino,

(24) pyrimidinylamino,

(25) quinolinylamino,

(26) heterocycle of from 5 to 8 nuclear members containing 1 nitrogen atom and up to 2 other hetero-atoms selected from sulfur, oxygen and nitrogen, and substituted with hydrogen, lower alkyl or phenyl,

R is a member selected from the group consisting of 1) hydrogen, and

(2) lower alkyl;

R and R when lower alkyl can be linked together to form a 3 to 6 membered heterocycle with the nitrogen atom to which they are attached, containing up to 1 other hetero atom selected from oxygen and nitrogen; and

R is lower alkyl.

2. A process as claimed in claim 1, wherein the reaction is carried out in a polar organic solvent at a temperature in the range from ambient to about C.

3. A process for the preparation of pyrazinamide compounds as claimed in claim 1 wherein R R R R*, R and R are as defined in claim 1 and R represents Ila wherein R is a member selected from the group consisting of (1) lower alkyl,

(3) halophenyl,

(4) lower alkyl-phenyl, and

(5) lower alkoxy-phenyl.

4. A process as claimed in claim 3, wherein the reaction is carried out in a polar organic solvent at a temperature in the range from ambient to about 150 C.

S. A process for the preparation of pyrazinamide compounds as claimed in claim 1 wherein R R R R R and R are as defined in claim 1 and R represents.

wherein R is a member selected from the group consisting of (1) hydrogen, and 2) lower alkvl:

R is a member selected from the group consisting of R is a member selected from the group consisting of 1) hydrogen, and (2) lower alkyl;

R and R when lower alkyl, can be linked together to form with the nitrogen atom to which they are attached, a heterocyclic ring;

R and R when lower alkyl, can be linked together to form with the nitrogen atoms to which they are attached, a heterocyclic ring.

6. A process as claimed in claim 5, wherein the reaction is carried out in a polar organic solvent at a temperature in the range from ambient to about 150 C.

7. A process for the preparation of pyrazinamide compounds as claimed in claim 1 wherein R R R R R and R are as defined in claim 1 and R represents wherein R represents a member selected from the group consisting of (1) hydrogen, and (2) lower alkyl;

R is a member selected from the group consisting of (1) hydrogen, (2) lower alkyl, (3) hydroxy-lower alkyl, (4) phenyl-lower alkyl, (5 phenyl, and (6) amino;

R is a member selected from the group consisting of (1) hydrogen,

(2) a hydrocarbon radical which when linked with R forms a diazacyclic ring with the nitrogens to which R and R are attached.

8. A process as claimed in claim 7, wherein the reaction is carried out in a polar organic solvent at a temperature in the range from ambient to about C.

9. A process for the preparation of pyrazinamide compounds as claimed in claim 1 wherein R R R R R and R are as defined in claim 1 and R represents NH I[\IH n -CNH C-NHO 1w wherein R is a member selected from the group consisting of (l) benzyl,

(2) lower alkyl-benzyl, (3) halobenzyl,

(4) nitrobenzyl, and (5) lower alkyl.

10. A process as claimed in claim 9, wherein the reaction is carried out in a polar organic solvent at a temperature in the range from ambient to about 150 C.

11. A process for the preparation of pyrazinamide compounds as claimed in claim 1 wherein R R R R R and R are as defined in claim 1 and R represents m -SO2N/ wherein R is a member selected from the group consisting of (1) hydrogen, (2) lower alkyl, (3) phenyl, and (4) phenyl-lower alkyl; and

R is a member selected from the group consisting of (1) hydrogen, and (2) lower alkyl.

12. A process as claimed in claim 11, wherein the reaction is carried out in a polar organic solvent at a temperature in the range from ambient to about 150 C.

13. The process as claimed in 5 wherein R is to yield a product of structural formula N (N N112 RZ l hal comer-cum n" N in wherein R R R, R and R and halo have the meanings assigned to each of them in claim 5.

14. The process as claimed in claim 13, wherein R R R, R and R are each hydrogen, and halo represents chloro to yield (3,S-diamino-6-chloropyrazinoyl)- quanidine.

15. The process as claimed in claim 13, wherein R and R each represent methyl, R, R and R each repreto yield a product of structural formula halo \N CONHNH o NR R wherein R R R R R and halo have the meanings assigned in claim 7.

17. The process as claimed in claim 16, wherein R R R R and R each represents hydrogen, and halo represents chloro to yield (3,5-diamino-6-chloropyrazinamido) guanidine.

18. The process as claimed in claim 1 wherein -R is a member selected from the group consisting of (1) lower alkyl,

(2) mono(lower alkoxy)methyl-lower alkyl,

(3) di(lower alkoXy)-methyl-lower alkyl,

(4) cyano-lower alkyl,

(5 lower alkoxycarbonyl-lower alkyl,

(6) phenyl-lower alkyl,

(7) quanidinocarbonyl-lower alkyl,

(8) quanidinoaminocarbonyl-lower alkyl,

(9) heterocyclic-lower alkyl-arninocarbonyl-lower alkyl, wherein the heterocycle is linked through a nuclear nitrogen and contains up to 1 other nuclear hetero atom selected from oxygen and nitrogen, which when nitrogen is substituted with hydrogen or lower alkyl,

(10) di (lower alkyl)aminomethyl-lower alkyl,

( 11) 2-(Z-imidazolinyl)aminomethyl-lower alkyl,

(12) heterocyclic-lower alkyl wherein the heterocycle is of 5 to about 8 nuclear members containing up to 2 heteroatoms selected from oxygen and nitrogen, either unsubstituted or substituted with lower alkyl.

(13) lower alkenyl,

(14) lower alkynyl,

( 15 phenyl,

(16) halophenyl,

(17 lower alkyl-phenyl,

(18) lower alkoxy-phenyl, and

(19) cyano,

and R R and halo have the meanings assigned therein. 19. The process as claimed in claim 1, wherein R is a member selected from the group consisting of (1) amino,

( 2) di (lower alkyl)amino,

(3) (phenyl-lower alkyl) (lower alkyl)amino,

(4) pyridylamino,

(5) pyrimidinylamino,

(6) quinolinylamino, and

(7 heterocycle of from 5 to 8 nuclear members containing 1 nitrogen atom and up to 2 other heteroatoms selected from sulfur, oxygen and nitrogen, and substituted with hydrogen, lower alkyl or phenyl,

and R R R R R R and halo have the meanings assigned therein.

20. The process as claimed in claim 11. wherein R R R R and R are hydrogen, and halo is chloro to produce 3,S-diamino-6-chloropyrazinoylsulfamide.

21. The process as claimed in claim 9, wherein R R and R are hydrogen; halo is chloro; and R is benzyl to produce 1-(3,5-diamino-6-chloropyrazinoyl)-5- benzyloxybiguanide.

22. The process as claimed in claim 1, wherein R is N-- 11 ra wherein R R and R are separately selected from hydrogen, lower alkyl and phenyl.

23. The process as claimed in claim 22 wherein R R R R R and R are hydrogen and halo is chloro, to produce N-(2-thiazolin-2-yl)-3,5-diamino-6-chloropyrazincarboxamide.

24. The com-pound represented by structural formula wherein R R R R R and halo each have the meaning assigned to them in claim 1.

25. The compound as claimed in claim 24, wherein R R and R each represents hydrogen, R represents methyl, R represents tertiary butyl, and halo represents chloro.

26. The compound as claimed in claim 24, wherein R R and R each represents methyl, R represents hydrogen, R represents tertiary butyl, and halo represents chloro.

27. The compound of structural formula halo -CONHCNHR wherein R and R are members selected from the group consisting of hydrogen and lower alkyl; halo is a member selected from the group consisting of chloro, bromo, and iodo; and R is a member selected from the group consisting of hydroxy, lower alkoxy, phenyl-lower alkoxy, cyano, and nitro.

28. 1-(3,5-diamino 6 chloropyrazinoyl)-3-hydroxyguanidine.

29. 1-(3-amino-5-dimethylamino 6 chloropyrazinoyl)-3-hydroxyguanidine.

30. 1-(3,5-diamino 6 chloropyrazinoyl)-3-methoxyguanidine.

31. 1-(3-amino-5-dimethylamino 6 chloropyrazinoyl) -3 -methoxyguanidine.

32. 1-(3,5-diamino 6 chloropyrazinoyl)-3-benzyloxyguam'dine.

33. 1-(3-amino-5-dimethylamino 6 chloropyrazinoyl -3-benzyloxyguanidine.

34. 1-(3,5-diamino 6 chloropyrazinoyl)-3-cyanoguanidine.

d 35. 1-(3,5-diarnino 6 chloropyrazinoyl)-3-nitroguani- 36. A compound of structural formula wherein R R and halo each have the meanings assigned to them in claim 1, and R is a member selected from the group consisting of:

(a) lower alkyl,

(c) halophenyl,

(d) lower alkyl-phenyl, and

(e) lower alkoxyphenyl.

37. A compound of structural formula N NI INK, Ru R I 1 N hao \N GO wherein R R and halo each have the meanings assigned to them in claim 1, and R is a member selected from the group consisting of: (a) mono(lower alkoxy)methyl-lower alkyl, (b) phenyl-lower alkyl, P y (d) halophenyl, (e) lower alkyl-phenyl, (f) lower alkoxy-phenyl, (g) lower alkoxycarbonyl-lower alkyl, (h) cyano-lower alkyl, (i) (2-imidazolin-2-yl)amino-lower alkyl, (j) lower alkoxycarbonyl, and (k) di(lower alkoxy) methyl-lower alkyl, and R is a member of the group consisting of hydrogen and lower alkyl.

42. A compound of structural formula wherein R R and halo each have the meanings assigned to them in claim 1, and R is a member of the group consisting of (a) benzyl,

(b) lower alkyl-benzyl,

(c) halobenzyl,

(d) nitrobenzyl, and

(e) lower alkyl.

, 40 43. 1 (3,S-diamino-6-chloropyrazinoy1)-5-benzyl-oxybiguanide.

44. A compound of structural formula wherein R R and R are members selected from the group consisting of hydrogen, and lower alkyl; and R R and halo have the meanings assigned in claim 1.

45. N-(2-thiazolin-2-y1)-3 ,5 -diamino-6-chloropyrazinecarboxamide hydrochloride hemihydrate.

46. A compound of structural formula wherein R is a member selected from the group consisting of (a) thiazol-Z-yl,

(b) 4phenylthiazol-2-yl, (c) 4-methylthiazol-2-yl, (d) pyrimidin-Z-yl,

(e) pyridin-4-yl,

(f) pyridin-Z-yl, and

(g) 5-phenyloxazolin-2-yl,

and R R and halo are as defined in claim 1.

47. The compound as claimed in claim 46, wherein halo is chloro and R and R are selected from hydrogen and lower alkyl.

48. A compound of structural formula N N NH, R R halo O-N N ll No. references cited.

NICHOLAS S. RIZZO, Primary Examiner US. Cl. X.R. 

